Circassia Pharmaceuticals, a specialty pharmaceutical company focused on respiratory disease, has received a multi-year Innovative Technology contract for its NIOX VERO® asthma management products from Vizient, Inc., the largest member-owned health care company in the United States.
Circassia’s NIOX VERO® range is used to assist asthma diagnosis and management and is based on the discovery that patients with Th2 or type 2 driven airway inflammation, the major underlying cause of asthma, generally have higher than normal levels of nitric oxide in their exhaled breath. By measuring the concentration of this fractional exhaled nitric oxide (FeNO), NIOX® enables clinicians to evaluate airway inflammation in patients with underlying asthma, aiding diagnosis and helping guide treatment and reduce exacerbations.
Steve Harris, Circassia’s CEO, said:
“Circassia is proud to be awarded this prestigious Vizient Innovative Technology contract, which recognises the important role NIOX VERO® plays in assisting asthma diagnosis and management. This new contract will provide Circassia with a simplified route to access Vizient members as potential new customers, helping us expand our number of accounts while offering savings opportunities for NIOX® users.”